This Analyst Has Patience When it Comes to Apple (AAPL) Stock; Here’s Why
Wedbush analyst Daniel Ives takes a metaphoric sigh after learning some negative news coming out of China’s People’s Court, which granted two preliminary …
Roku (ROKU) Stands Ground Against Potential Apple TV Competition; Analyst Weighs in on the Stock
Rumors are spreading that Apple is considering making a lower-priced connected TV dongle for its Internet TV platform to-be. Though it is unclear …
Laying Out a Realistic Bear Case for General Electric (GE) Stock: Deutsche Bank
General Electric (GE) has been a symbol of America’s strength. But over the past few years, the company has, instead, been a symbol …
MYOS RENS Technology (MYOS) Stock Fires Up to the Roof; Here’s Why
MYOS RENS Technology (MYOS) stock is soaring — up over 50% since news broke today that The Vitamin Shoppe is picking up its product …
Should You Blindly Follow Facebook (FB) Stock Along the Buyback?
During a time where Facebook (FB) management is under fire, negative press has taken a toll on its stock and even users feel …
Square’s (SQ) Proven Track Record Should Be Enough Incentive to Buy Stock
Top blogger Bill Maurer is encouraging investors to buy Square (SQ) shares after the stock fell around 7% amid a market selloff and …
Gilead Sciences (GILD) Stock: Analyst Believes New CEO Could Be a Game-Changer
Congrats! Gilead Sciences (GILD) has just appointed Daniel O’Day as the Chief Executive Officer of the pharmaceutical giant.
MacroGenics (MGNX) Stock Tumbles After Clinical Hold on Early-Stage Study — Yet This Analyst Bulls Ahead
After the markets closed Friday, MacroGenics (MGNX) announced a partial clinical hold on its Phase 1 monotherapy study of MGD009, a bispecific antibody developed under …
A Glimpse Into the Cannabis Stocks’ World
Investing in the marijuana industry may have seemed taboo a few years back, but as more states are making recreational marijuana legal with …
Marinus Pharmaceuticals (MRNS) Sparks Optimism Among Investors; Here’s Why
Marinus Pharmaceuticals (MRNS) just released positive results from its Phase 2 clinical trials, which evaluated ganaxolone intravenous (IV) (called the Magnolia Study) and …